Kimulique Allen
Internal Medicine · Dallas, TXNPI 1801836713
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations.
Across 122 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$254
- AstraZeneca$247
- Amgen$157
- Novo Nordisk$136
- Pfizer$128
- Amarin Pharma, Inc.$118
- plus $743 from 17 others
What the payments were for
- Food & beverage$1,783100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 18 | $254 |
| AstraZeneca | 17 | $247 |
| Amgen | 9 | $157 |
| Novo Nordisk | 12 | $136 |
| Pfizer | 9 | $128 |
| Amarin Pharma, Inc. | 6 | $118 |
| Astellas Pharma US Inc | 5 | $100 |
| GSK | 6 | $89 |
| Arbor Pharmaceuticals, Inc. | 6 | $82 |
| AbbVie | 6 | $74 |
| Merck | 6 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Boehringer Ingelheim | 3 | $48 |
| Radius Health, Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Sanofi-aventis U.S. LLC | 3 | $37 |
| Novartis | 2 | $32 |
| Antares Pharma, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Lilly USA, LLC | 1 | $11 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$1,783 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 17 | $352 |
| Naratriptan Hcl | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Dallas
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Han SchmidlyDallas$465K
- Athica VatanapradithDallas$164K
- Nicholaos BellosDallas$113K
- Steven HeldDallas$65K
- Amit VermaDallas$53K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Mohammed Al-NajjarEl Paso$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.